

Review Article

Efficacy and Adverse Effects of Atropine for Myopia Control in Children: A Meta-Analysis of Randomised Controlled Trials

ChunWen Chen 🕞 and JingYan Yao 🕞

Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou, China

Correspondence should be addressed to JingYan Yao; yjysdfy@163.com

Received 26 September 2021; Accepted 18 November 2021; Published 10 December 2021

Academic Editor: Shengjie Li

Copyright © 2021 ChunWen Chen and JingYan Yao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. To explore the rebound effects and safety of atropine on accommodation amplitude in slowing myopia progression. *Methods.* We conducted a meta-analysis to testify proper dosage of atropine in children with myopia. We searched in PubMed, EMBASE, Ovid, and the Cochrane Library up to March 30, 2021. We selected randomised controlled trials (RCTs) that evaluated the efficacy of atropine for controlling myopia progression in children. We performed the inverse variance random-effects model to pool the data using mean difference (MD) for continuous variables. Statistical heterogeneity was assessed using the I² test. Additionally, we conducted subgroup analyses and sensitivity analyses. *Results.* Seventeen RCTs involving 2955 participants were included. Myopia progression was significantly less in the atropine group than that of the control group, with MD = 0.38 D per year (95% confidence interval, 0.20 to 0.56). Less axial elongation was shown with MD = -0.19 mm per year (95% CI, -0.25 to -0.12). There was a statistically difference among various doses (p = 0.00001). In addition, 1.0% atropine showed the rebound effect with MD = -0.54 D per year (95% CI, -0.81 to -0.26) and was more effective in the latter six months than in the former one. Less accommodation amplitude was shown in 0.01% atropine. *Conclusion.* The efficacy of atropine is dose dependent, and 0.01% atropine may be the optimal dose in slowing myopia progression in children with no accommodation dysfunction. A rebound effect is more prominent in high-dose atropine in the former cessation after discontinuation.

1. Introduction

Myopia, known as nearsightedness, is widely recognized as an urgent public health issue causing significant visual loss for a range of ocular comorbidities including cataract, retinal detachment, and glaucoma [1–3]. The high prevalence has been reported to be 80–90% in school children in certain East Asian areas in the past few decades [4–6]. The worldwide prevalence of myopia and high myopia is estimated to increase affecting nearly five and one billion people globally, respectively, by the year 2050 [7]. This silent epidemic should not be ignored [8]. Furthermore, early-onset myopic children are always accompanied with high progression rates and a higher incidence of high myopia [9, 10]. Thus, it is instant to prevent myopia promptly. The currently considered therapies for myopia include optical correction including bifocal spectacle lenses, orthokeratology lenses, multifocal contact lenses, additional time spent outdoor, and pharmaceutical agents such as topical atropine [6, 11, 12].

Atropine (low dose, 0.01%; moderate dose, 0.01% to 0.5%; and high dose, 1%) has been used to control myopia progression for many years [13–15]. The exact mechanism of how atropine retards is still unclear that may alter corneal curvature, vitreous chamber depth, lens thickness (LT), and anterior chamber depth (ACD) [16, 17]. The low-dose atropine has minimal influence on pupil size, loss of accommodation, and near vision for the prevention of myopia progression [14]. Patients using atropine may experience blurred vision, glare, photophobia, and allergic reactions [18]. In the recent findings, 0.05% atropine seemed to be the most effective dosage in myopia prevention [18]. One study demonstrated that atropine also caused a reduced myopic progression and rebound effect, which was less pronounced with lower dosage [19].

However, previous systematic review and meta-analysis have identified the efficacy and safety of atropine with ambiguous findings [20-23]. It was shown that the optimal dose of atropine may be 0.5% and 1% by Song et al. [21] and equally beneficial by Gong et al. [20], 0.01% by Zhao et al. [22], and 0.05% by Zhao et al. [23], but lacking consensus on atropine dose. As new clinical trials continually emerge, it is essential to conduct a meta-analysis to identify the optimal dose of atropine. The purpose of this study was to investigate the efficacy and rebound effects of different concentrations after its cessation and compare the rate of progression earlier and later during the first year. Moreover, the present analysis evaluated various doses of atropine with primary adverse effects on accommodation and ACD. Other adverse effects of atropine were analyzed including best-corrected visual acuity (BCVA), near vision, pupil size, intraocular pressure (IOP), tear break-up time (T-BUT), and LT.

2. Methods

This was a meta-analysis of existing RCTs; thus, approval by the institutional review board was not required.

2.1. Data Sources and Literature Searches. We searched PubMed, EMBASE, Ovid, and the Cochrane Library for RCTs in any languages to yield relevant studies from their inception to March 30, 2021. We used the following as key words: myopia, refractive errors, and atropine, as well as some relevant free terms. We also screened in the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov to retrieve additional ongoing trials. We used a protocol for the present review registered in the PROSPERO database (CRD42021247893).

2.2. Study Selection. We included only RCTs according to the following criteria: (1) participants were younger than 18 years with myopia; (2) atropine was used for at least one treatment arm, and (3) the study reported at least one outcome of interest, including the mean myopia progression (D per year), axial elongation, pupil size, accommodation amplitude, and any adverse effects. The exclusion criteria were as follows: (1) secondary articles such as review articles; (2) original data could not be extracted and obtained after contacting the author.

2.3. Data Collection. Two reviewers (Chun-Wen Chen and Jing-Yan Yao) independently screened data. In case of more than one data report from the same study, we included only the latest report to avoid duplicate counting of the data. Data from all doses were recognized as unique clinical trials. We conducted a focused discussion to resolve any disagreements. We extracted the following information from each trial: (1) study characteristics (author, year of publication, country, intervention and control group, and follow-up duration); (2) patient characteristics (the number of cases and age and baseline refraction).

2.4. Risk of Bias Assessment. We assessed the risk for bias of RCTs for the following six aspects according to the Cochrane Collaboration: random sequence generation, allocation concealment, blinding of patients and personnel, masking of outcome assessors, incomplete outcome data, and selective outcome reporting. We graded each of the item domains at "low," "high," or "unclear" risk of bias.

2.5. Statistical Analysis. We conducted analyses for changes in different concentrations of atropine versus control conditions based on RCTs. We calculated mean difference (MD) and 95% confidence intervals (CIs). We assessed heterogeneity with the I² statistic. Also, I² value greater than 50% indicates substantial heterogeneity. Subsequently, we considered performing sensitivity and subgroup analyses to investigate the source of heterogeneity. We performed direct comparisons using Review Manager (version 5.3; Cochrane Collaboration). For all comparisons, the stated values represent differences in final outcome between the intervention and control group. In terms of refractive diopters, a positive MD indicates that the intervention is better (less myopia progression). In terms of axial length, a negative MD indicates the intervention is better (less axial elongation). p value was thought to be significantly meaningful if less than 0.01.

3. Results

3.1. Study Characteristics. We identified 1163 studies through literature searches, and the remaining 45 full-text articles and, ultimately, 17 RCTs [13, 15, 16, 23–36] constituted the data for analysis (Figure 1). A total of 2955 participants were included comprising 1584 and 1371 in the intervention and control groups. The characteristics of the included studies are described in Table 1. Low-dose atropine (0.01%) was reviewed in eight studies [13, 23, 25, 27, 30, 31, 33, 36], moderate-dose atropine (0.01% to 0.5%) in four studies [13, 28, 29, 34], and high-dose atropine (1%) in five studies [15, 16, 24, 32, 35] together resulting in 21 interventional groups in 17 studies.

4. Methodology Quality Assessment

The quality of the included RCTs is shown in the supplementary materials (Figure S1). Overall, the trials seem to have a moderate risk of bias, with most of the trials reporting adequate random sequence generation, allocation concealment, and blinding of outcome assessment.

4.1. Efficacy Analysis

4.1.1. Spherical Equivalent Refraction (SER). Data on annual rate of myopia progression were available from all studies. The progression of myopia was defined as the changes in SER relatively to baseline. The overall heterogeneity I² was 99%, so a subgroup analysis was performed. The pooled data showed significantly progression for low dose (MD, 0.26 D per year; 95%CI, 0.15 to 0.37) and moderate dose (MD, 0.59 D per year; 95%CI, 0.41 to 0.78) compared to the control group. No statistically difference was found in high dose (p = 0.32).



FIGURE 1: Flowchart for the study analysis. ICTRP = International Clinical Trials Registry Platform; RCTs = randomized controlled trials.

			eteriories and demographics of	moradoa oradicoi			
Author (y)	Country	Follow-up, mos	Intervention group	Control group	Ν	Age (y)	Baseline refraction
Chua et al., 2006 [24]	Singapore	24	1% ATE	Placebo	156/ 190	6~12	-1.00 D to -6.00 D
Diaz-Llopis et al., 2018 [25]	Spain	60	0.01% ATE	Placebo	100/ 100	9~12	-0.50 D to -2.00 D
Hieda et al., 2021 [26]	Japan	24	0.01% ATE	Placebo	85/86	6~12	-1.00 D to -6.00 D
Kumaran et al., 2015 [16]	Singapore	36	1% ATE	Placebo	147/ 166	6~12	-1.00 D to -6.00 D
Saxena et al., 2021 [27]	India	12	0.01%ATE	Placebo	50/50	6~14	−0.5 D to −6.00 D
Shih et al., 1999 [28]	Taiwan	24	0.5%, 0.25%, 0.1% ATE	Tropicanide	137/49	6~13	–0.5 D to –6.75 D
Shih et al., 2001 [29]	Taiwan	18	0.5% ATE + multifocal	Multifocal	66/61	6~13	Mean, -3.28 D
Tan et al., 2020 [30]	Hong Kong	12	0.01% ATE + OK lens	OK lens	29/30	6~11	-1.00 D to -4.00 D
Tang et al., 2020 [31]	China	12	0.01% ATE	Placebo	63/63	8~14	-0.50 D to -6.00 D
Tong et al., 2009 [32]	Singapore	36	1% ATE	Placebo	158/ 175	6~12	-1.00 D to -6.00 D
Vincent et al., 2020 [33]	Hong Kong	6	0.01% ATE + OK lens	OK lens	25/28	6~11	-1.00 D to -4.00 D
Wang et al., 2017 [34]	China	12	0.5% ATE	Placebo	63/63	5~10	-0.50 D to -2.00 D
Wei et al., 2020 [36]	China	12	0.01% ATE	Placebo	76/83	6~12	-1.00 D to -6.00 D
Yam et al., 2018 [13]	Hong Kong	12	0.05%, 0.025%, 0.1% ATE	Placebo	290/93	4~12	<-1.0 D D
Yen et al., 1989 [35]	Taiwan	12	1% ATE	Placebo	32/32	6~14	-0.5 D to -4.00 D
Yi et al., 2015 [15]	China	12	1% ATE	Placebo	68/64	7~12	-0.50 D to -2.00 D
Zhao and Hao, 2021 [23]	China	12	0.01% ATE + OK lens or spectacles	OK lens or spectacles	40/40	5~14	-1.00 D to -6.00 D

TABLE 1: Characteristics and demographics of included studies.

Y, year; mos, months; N, number; ATE, atropine; OK lens: orthokeratology lens; D, diopters; -, none.

There was a significant difference between the intervention and control group (Z = 4.26, p < 0.0001). The overall effect was 0.38 D per year (95% CI, 0.20 to 0.56), as shown in Figure 2(a).

4.1.2. Axial Elongation. Sixteen trials from fourteen studies [13, 15, 16, 23, 24, 26, 27, 29, 34, 36] reported changes in axial length. The overall heterogeneity I^2 was 98%, so a subgroup

	AT	E grou	ıp	Cont	trol gro	oup	Weight	Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% CI	IV, Random, 95% Cl
1% ATE									
Chua et al, 2006	-0.14	0.91	156	-0.6	0.35	190	4.9	0.46 [0.31, 0.61]	T
Kumaran et al, 2015	-0.44	0.28	147	-0.51	0.8	166	5.0	0.07 [-0.06, 0.20]	T
Tong et al, 2009	-1.14	0.8	158	-0.38	0.39	175	5.0	-0.76 [-0.90, -0.62]	
Yen et al, 1989	-0.22	0.54	32	-0.91	0.58	32	4.6	0.69 [0.42, 0.96]	
Yi et al, 2015	0.32	0.22	68	-0.85	0.31	64	5.1	1.17 [1.08, 1.26]	-
Subtotal (95% CI) Heterogeneity: $tau^2 = 0.70$ Test for overall effect: $Z =$; chi ² = 0.86 (P	567.63 = 0.39	561 , df =	4 (<i>P</i> < 0	0.00001	627); $I^2 =$	24.6 99%	0.33 [-0.41, 1.06]	
		,							
0.01%-0.5% ATE									
Shih et al, 1999(0.10%)	-0.04	0.63	41	-1.06	0.61	49	4.6	1.02 [0.76, 1.28]	
Shih et al, 1999(0.50%)	-0.47	0.91	49	-1.06	0.61	49	4.5	0.59 [0.28, 0.90]	
Shih et al, 1999(0.25%)	-0.45	0.55	47	-1.06	0.61	49	4.7	0.61 [0.38, 0.84]	
Shih et al, 2001	-0.42	0.07	66	-1.19	0.07	61	5.1	0.77 [0.75, 0.79]	
Wang et al, 2017	-0.5	0.5	63	-0.8	0.6	63	4.8	0.30 [0.11, 0.49]	
Yam et al, $2018(0.025\%)$	-0.46	0.45	91	-0.81	0.53	93	5.0	0.35 [0.21, 0.49]	
Y am et al, 2018(0.05%)	-0.27	0.61	102	-0.81	0.53	93	4.9	0.54 [0.38, 0.70]	
Subtotal (95% CI)	-1. :2	(7.10	459	(D . 0)	00001)	45/	33./	0.59 [0.41, 0.78]	•
Test for overall effect: $Z =$	$; cm^2 = 6.25 (P)$	67.19, < 0.000	df = 6 001)	P < 0.0	00001)	; 1- = 9	1%		
0.01% ATE									
Diaz et al. 2018	-0.14	0.35	100	-0.65	0.54	100	5.0	0.51 [0.38, 0.64]	÷
Hieda et al. 2021	-1.26	0.09	84	-1.48	0.09	84	5.1	0.22 [0.19, 0.25]	
Saxera et al. 2021	-0.16	0.4	50	-0.35	0.4	50	4.9	0.19 [0.03, 0.35]	-
Tan et al. 2020	2.95	1	29	2.87	0.97	30	3.6	0.08[-0.42, 0.58]	
Tang et al. 2020	-0.16	0.06	63	-0.2	0.09	63	5.1	0.04 [0.01, 0.07]	
Vincent et al. 2020	1.48	1.08	25	1.49	1.18	28	3.2	-0.01 [-0.62, 0.60]	
Wei et al. 2020	-0.49	0.42	76	-0.76	0.5	83	5.0	0.27 [0.13, 0.41]	x
Yam et al. 2018	-0.59	0.61	97	-0.81	0.53	93	4.9	0.22 [0.06, 0.38]	T
Zhao et al, 2021	-0.25	0.16	40	-0.82	0.59	40	4.8	0.57 [0.38, 0.76]	-
Subtotal (95% CI)			564			571	41.8	0.26 [0.15, 0.37]	♦
Heterogeneity: $tau^2 = 0.02$ Test for overall effect: $Z =$; chi ² = 4.49 (P	144.42 < 0.000	, df = 001)	8 (<i>P</i> < 0	.00001); <i>I</i> ² =	94%		
Total (95% CI)			1584			1655	100.0	0 38 [0 20 0 56]	•
Heterogeneity: $tau^2 = 0.16$: chi ² =	2369 7	'0. df =	$= 20 (P \cdot$	< 0.000	$(01): I^2$	= 99%		I I
Test for overall effect: $Z =$	4.21 (P	< 0.000	(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0	20 (1	. 0.000	51),1	22,0		-2 -1 0 1 2
Test for subgroup differen	ces: chi ²	$^{2} = 8.9^{2}$	7, df =	= 2 (P =	0.01):1	$1^2 = 77$.7%		ATE group Control group
0 1				`	. ,)-				

(a) FIGURE 2: Continued.

	E grou	р	Cont	trol gro	up	up Weight Mean difference		Mean difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% CI		IV, R	andom, 95	% CI	
1% ATE													
Chua et al, 2006	-0.02	0.35	156	0.38	0.38	190	6.4	-0.40 [-0.48, -0.32]			*		
Kumaran et al, 2015	0.26	0.27	147	0.53	0.46	166	6.3	-0.27 [-0.35, -0.19]			-		
Tong et al, 2009	0.29	0.37	158	0.52	0.45	175	6.3	-0.23 [-0.32, -0.14]			-		
Yi et al, 2015	-0.03	0.07	64	0.32	0.15	68	6.9	-0.35 [-0.39, -0.31]					
Subtotal (95% CI)			525			599	25.9	-0.32 [-0.38, -0.25]			•		
Heterogeneity: $tau^2 = 0.00$ Test for overall effect: $Z =$; chi ² = 9.35 (P	11.10, < 0.000	df = 3 001)	(P = 0.0)	01); I ²	= 73%							
0.01%-0.5% ATE													
Shih et al, 2001	0.22	0.03	66	0.49	0.03	61	7.1	-0.27 [-0.28, -0.26]			1.1		
Wang et al, 2017	-1.1	1.73	63	0.5	1.73	63	1.0	-1.60 [-2.20, -1.00]					
Yam et al, 2018(0.025%)	0.29	0.2	91	0.41	0.22	93	6.7	-0.12 [-0.18, -0.06]			*		
Yam et al, 2018(0.05%)	0.2	0.25	102	0.41	0.22	83	6.6	-0.21 [-0.28, -0.14]			.		
Subtotal (95% CI)			322			310	21.3	-0.25 [-0.37, -0.13]			•		
Heterogeneity: $tau^2 = 0.01$ Test for overall effect: $Z = 0.01$	$chi^2 = 4.09 (P)$	44.21, < 0.000	df = 3 01)	(<i>P</i> < 0.0	00001)	$I^2 = 9$	93%						
0.01% ATE													
Hieda et al, 2021	0.63	0.04	84	0.77	0.04	86	7.1	-0.14 [-0.15, -0.13]					
Saxera et al, 2021	0.22	0.2	50	0.28	0.28	50	6.1	-0.06 [-0.16, -0.04]			-		
Tan et al, 2020	0.07	0.16	29	0.16	0.15	30	6.4	-0.09 [-0.17, -0.01]			-		
Tang et al, 2020	0.18	0.06	63	0.16	0.06	63	7.0	0.02 [-0.00, -0.04]					
Vincent et al, 2020	-0.01	0.12	25	0.05	0.08	28	6.7	-0.06 [-0.12, -0.00]			-		
Wei et al, 2020	0.32	0.19	76	0.41	0.19	83	6.7	-0.09 [-0.15, -0.03]			~		
Yam et al, 2018(0.01%)	0.36	0.29	97	0.41	0.22	93	6.5	-0.05 [-0.12, -0.02]			-		
Zhao et al, 2021	0.19	0.11	40	0.51	0.27	40	6.2	-0.32 [-0.41, -0.23]			-		
Subtotal (95% CI)			464			473	52.8	-0.10 [0.17, 0.02]			•		
Heterogeneity: $tau^2 = 0.01$ Test for overall effect: $Z =$	$chi^2 = 2.65 (P)$	195.91 = 0.008	, df = 8)	7 (<i>P</i> < 0	0.00001); $I^2 =$	96%						
							100.0						
Total (95% CI)			1311			1382	100.0	-0.19 [0.25, -0.12]			•		
Heterogeneity: $tau^2 = 0.02$	$chi^2 =$	866.59	, df =	15 (<i>P</i> <	0.0000	1); I^2 :	= 98%		_2	_1	0	1	2
Lest for overall effect: $Z =$	5.77 (P	< 0.000)1)			2			4	ATE ~		 41	
	1.0	2	10	0 (F	0 0 0 0	• • • • • • • • • • • • • • • • • • • •	00 10/			/	P(1111) 1 (1)	TROL (TROVING	

FIGURE 2: Forest plot of the effects of atropine on SER (a) and axial elongation (b). SER, spherical equivalent refraction; CI, confidence interval.

analysis was performed. The data showed significantly less axial elongation for low dose (MD, -0.10 mm per year; 95% CI, -0.17 to -0.02), moderate dose (MD, -0.25 mm per year; 95% CI, -0.37 to -0.13), and high dose (MD, -0.32 mm per year; 95% CI, -0.38 to -0.25) compared to the control group. The combined results demonstrated that atropine yields significantly greater improvement in myopia progression (p < 0.00001). The analyses reported that the overall MD was -0.19 mm per year (95% CI, -0.25 to -0.12), as shown in Figure 2(b).

4.1.3. Rebound Effects. Four trials from two studies [16, 32] assessed the changes in SER. The overall heterogeneity I^2 was 96%, so a subgroup analysis by variable of follow-up period was performed. The overall MD was -0.54 D per year (95% CI, -0.81 to -0.26) in high dose. Besides, there was significant difference between the first six months (MD, -0.81 D per year; 95% CI, -1.37 to -0.26) and the latter (MD, -0.28

D per year; 95%CI, -0.45 to -0.10) after discontinuation, indicating the annual rate of myopia progression was higher in short period of cessation (Figure 3(a)). There was a statistically significant difference that favored high-dose atropine (p < 0.00001).

4.1.4. Adverse Effects. (1) Accommodation dysfunction: there were seven trials from five studies [13, 30–33] reporting data on changes of accommodation amplitude (AMP). The overall heterogeneity I² was 69%, so a subgroup analysis was performed. The AMP was significantly reduced by 0.71 ± 0.58 D (p = 0.02), respectively. Conversely, no statistically difference was identified in the low-dose atropine group (p = 0.49, Figure 3(b)).

(2) Pupil size: we performed an analysis of changes in photopic [13, 30, 31, 33] and mesopic size [13, 30, 33] in six trials. The overall heterogeneity I^2 was 69%, so a subgroup analysis was performed. There was a statistically significant difference in both

	ATE	grou	p T i l	Cont	rol gro	up	Weight	Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% CI	IV, Random, 95% Cl
7.1.1 24-30 mos									
Tong et al, 2009	-1.51	1.4	158	-0.4	0.65	175	22.3	-1.11 [-1.35, -0.87]	
Kumaran et al, 2015	-0.74	0.42	147	-0.2	0.32	166	26.2	-0.54 [-0.62, -0.46]	
Subtotal (95% CI)			305			341	48.5	-0.81 [-1.37, -0.26]	
Heterogeneity: $tau^2 = 0$).15; chi	$^{2} = 19$.53, df	= 1 (P <	< 0.000	01); I ²	= 95%		
Test for overall effect:	Z = 2.86	(<i>P</i> =)	0.004)						
7.1.2 30-36 mos									
Tong et al, 2009	-0.76	0.7	158	-0.38	0.58	175	25.1	-0.38 [-0.52, -0.24]	-
Kumaran et al, 2015	-0.35	0.33	147	-0.15	0.28	166	26.4	-0.20 [-0.27, -0.13]	
Subtotal (95% CI)			305			341	51.5	-0.28 [-0.45, -0.10]	•
Heterogeneity: $tau^2 = 0$).01; chi	$^{2} = 5.2$	20, df =	= 1 (P =	0.02);	$I^2 = 81$	%		
Test for overall effect:	Z = 3.13	(<i>P</i> =)	0.002)		,,				
Total (95% CI)			610			682	100.0	-0.54 [-0.81, -0.26]	•
Heterogeneity: $tau^2 = 0$).07: chi	$^{2} = 76$.68. df	= 3 (P <	< 0.000	$(01); I^2$	= 96%		
Test for overall effect:	Z = 3.85	(P = 0)	0.0001)		. ,)=			-2 -1 0 1 2
Test for subgroup diffe	rences	chi ² –	3 20	/ df = 1 (1	2-00	7). $I^2 -$	68.8%		ATE group Control group
Test for subgroup diffe	rences.	um =	5.20,	$u_1 = 1$ (1	r = 0.0	/);1 =	00.070		8F 8F

(a)												
	AT	E grou	ıp	Cont	rol gro	oup	Weight	Mean difference	Mean difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% CI	IV, Random, 95% CI			
11.1.1 0.01% ATE												
Tong et al, 2020	-1.1	1.8	29	-0.7	2.3	30	12.6	-0.40 [-1.45, 0.65]				
Tang et al, 2020	-1.54	1.95	63	-0.17	2.12	63	16.2	-1.37 [-2.08, -0.66]				
Vincent et al, 2020	1.2	2.1	25	-0.5	2.4	28	11.2	0.70 [-0.51, 1.91]				
Yam et al, 2018(0.01%)	-0.26	3.04	97	-0.32	2.91	93	14.7	0.06 [-0.79, 0.91]				
Subtotal (95% CI)			214			214	54.7	-0.32 [-1.22, 0.58]				
Heterogeneity: $tau^2 = 0.61$;	$chi^{2} = 1$	1.23,	df = 3	(P = 0.0)	1); $I^2 =$	73%						
Test for overall effect: $Z = 0$.70 (P =	0.49)										
11.1.2 0.01%~1% ATE												
Tong et al, 2009	0.89	3.76	158	1.42	3.96	175	14.9	-0.53 [-1.36, 0.30]				
Yam et al, 2018(0.025%)	-1.61	2.61	91	-0.32	2.91	93	15.2	-1.29 [-2.09, -0.49]				
Yam et al, 2018(0.05%)	-1.98	2.82	102	-0.32	2.91	93	15.2	-1.66 [-2.47, -0.85]				
Subtotal (95% CI)			351			361	45.3	–1.17 [–1.81, –0.52]				
Heterogeneity: $tau^2 = 0.15$;	$chi^2 = 3$.79, d	f = 2(1)	P = 0.15); $I^2 = 4$	47%						
Test for overall effect: $Z = 3$.55 (P =	0.000)4)									
Total (95% CI)			565			575	100.0	-0.71 [-1.30, -0.13]				
Heterogeneity: $tau^2 = 0.42$;	$chi^2 = 1$	9.09,	df = 6	(P = 0.00)	$()4); I^2$	= 69%	,					
Test for overall effect: $Z = 2$.38 (P =	0.02)							-2 -1 0 1 2			
Test for subgroup differenc		ATE group Control group										
							(b)					

FIGURE 3: Forest plot of rebound effects (a) and AMP (b). AMP, accommodation amplitude; CI, confidence interval.

factors (p < 0.00001). Low dose showed less influence on photopic pupil size than high dose (MD = 0.48 mm, 95%CI, 0.32 to 0.63), as shown in Figure 4 (p = 0.07).

4.1.5. BCVA. Seven trials from five studies [13, 15, 30–32] reported data in changes on BCVA. The overall heterogeneity I^2 was 38%. No statistically significance was shown in low-dose atropine (MD = 0.01 log MAR, 95%CI, -0.00 to 0.01). The pooled data showed significance in the high-dose group (MD, 0.02 log MAR; 95% CI, 0.01 to 0.03), as shown in Figure 4.

4.1.6. ACD, Near Vision, LT, IOP, and T-BUT. The overall heterogeneity I^2 was 95% in LT and 65% in ACD. No heterogeneity was detected in near vision, IOP, and T-BUT.

No statistically significant difference was found between the atropine and control groups in changes in ACD, near vision, LT, IOP, and T-BUT, as shown in Figure 4 (p > 0.05).

4.1.7. Publication Bias. We performed a funnel plot using a random-effects model, and the effect size was Z = 4.26 (p < 0.0001). Publication bias may exist within the included studies (Figure S2).

4.1.8. Sensitivity Analysis. We conducted a sensitivity analysis to determine the source of heterogeneity by removing studies one by one. We found limited difference between these trials, indicating that the results were relatively stable. A severe degree of heterogeneity was identified

	ATI	Egroup	Cont	rol gro	oup	Weight	Mean difference	Mean difference
Study or Subgroup	Mean	SD Total	Mean	SD	Total	%	IV, Random, 95% CI	IV, Random, 95% CI
0.01% ATE								
Tong et al, 2009	-0.05	0.07 158	-0.06	0.06	175	66.3	0.00 [-0.01, 0.01]	-
Yam et al, 2018(0.01%)	-0.03	0.13 97	-0.02	0.11	93	11.2	-0.01 [-0.04, 0.02]	
Subtotal (95% CI)		255			268	77.6	-0.00 [-0.01, 0.01]	•
Heterogeneity: $chi^2 = 0.28$,	df = 1 (l)	$P = 0.60); I^2$	= 0%					
Test for overall effect: $Z = 0$	0.22 (P =	0.83)						
17.1.2 0.01%-0.5% ATE								
Yam et al, 2018(0.025%)	0	0.13 91	-0.02	0.11	93	10.8	0.02 [-0.01, 0.05]	
Yam et al, 2018(0.05%)	-0.01	0.13 102	-0.02	0.11	93	11.6	0.01 [-0.02, 0.04]	
Subtotal (95% CI)		193			186	22.4	0.01 [-0.01, 0.04]	•
Heterogeneity: $chi^2 = 0.15$,	df = 1 (1)	$P = 0.69$; I^2	= 0%					
Test for overall effect: $Z = 1$.20 (P =	0.23)						
Total (95% CI)		448			454	100.0	0.00 [-0.01, 0.01]	•
Heterogeneity: $chi^2 = 1.79$,	df = 3(1)	$P = 0.62$; I^2	= 0%					
Test for overall effect: $Z = 0$.38 (P =		-0.2 -0.1 0 0.1 0.2					
Test for subgroup difference	es: chi ²		ATE group Control group					





	ATI	Egrou	р	Cont	rol gro	oup	Weight	Mean difference		Me	an differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% C	Ι	IV, R	andom, 95	5% CI	
0.01% ATE													
Tan et al, 2020	0.35	0.34	29	0.02	0.25	30	20.1	0.34 [0.18, 0.50]				-	
Yam et al, 2018(0.01%)	0.49	0.8	97	0.13	1.07	93	14.5	0.36 [0.09, 0.63]				_	
Tong et al, 2009	0.45	0.28	25	-0.05	0.03	28	20.2	0.51 [0.35, 0.67]				-	
Yam et al, 2018(0.01%)	0.74	0.6	63	0.05	0.55	63	17.9	0.69 [0.49, 0.89]				-	
Subtotal (95% CI)			214			214	72.8	0.48 [0.32, 0.63]					
Heterogeneity: $tau^2 = 0.02$;	$chi^2 = 8$.05, df	= 3 (1	P = 0.05); $I^2 =$	63%							
Test for overall effect: $Z = 6$.02 (P <	0.000	01)										
0.01%-0.5% ATE													
Yam et al, 2018(0.025%)	0.76	0.9	91	0.13	1.07	93	13.8	0.63 [0.34, 0.92]			-		
Yam et al, 2018(0.05%)	1.03	1.02	102	0.13	1.07	93	13.4	0.90 [0.61, 1.19]					
Subtotal (95% CI)			193			186	27.2	0.76 [0.50, 1.03]				•	
Heterogeneity: $tau^2 = 0.01$;	$chi^2 = 1$.67. df	= 1 (1)	P = 0.20); $I^2 =$	40%							
Test for overall effect: $Z = 5$	6.65 (P <	0.000	01)										
Total (95% CI)			407			400	100.0	0.56 [0.40, 0.71]			•	•	
Heterogeneity: $tau^2 = 0.03$;	$chi^2 = 1$	6.01, d	f = 5	(P = 0.0)	07); I^2	= 69%			-2	-1	0	1	2
Test for overall effect: $Z = 6.92$ ($P < 0.00001$) Test for subgroup differences: chi ² = 3.31, df = 1 ($P = 0.07$); $I^2 = 69.8\%$									-	ATE gi	oup Con	itrol group	-

							(c)						
	ATE	Egrou	р	Cont	trol gro	up	Weight	Mean difference		Mean difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% C	Ι	IV, Ra	ndom, 95	5% CI	
0.01% ATE Tan et al, 2020 Vincent et al, 2020 Yam et al, 2018(0.01%) Subtotal (95% CI)	0.64 0.66 -0.03	1.48 0.76 0.06	29 25 97 151	0.1 0.09 0.02	0.5 0.9 0.55	30 28 0 58	17.2 5.4 22.6	0.54 [0.29, 0.79] 0.57 [0.12, 1.02] Not estimable 0.55 [0.33, 0.77]			-	•	-
Heterogeneity: $chi^2 = 0.01$, Test for overall effect: $Z = 4$	df = 1 (<i>I</i> .91 (<i>P</i> <	P = 0.9 0.000	01); <i>I</i> ² 01)	= 0%									
0.01%-0.5% ATE Yam et al, 2018(0.025%) Yam et al, 2018(0.05%) Subtotal (95% CI) Heterogeneity: $chi^2 = 1.55$, Test for overall effect: $Z = 8$	0.43 0.58 df = 1 (<i>P</i> 3.08 (<i>P</i> <	0.61 0.63 P = 0.2 0.000	91 102 <i>193</i> 21); <i>I</i> ² 01)	0.02 0.02 = 36%	0.55 0.55	93 93 186	38.2 39.2 77.4	0.41 [0.24, 0.58] 0.56 [0.39, 0.73] 0.49 [0.37, 0.60]				•	
<i>Total</i> (95% <i>CI</i>) Heterogeneity: $chi^2 = 1.80$, Test for overall effect: <i>Z</i> = 9 Test for subgroup difference	df = 3 (I) 0.44 (P < tes: chi ² =	^D = 0.6 0.000 = 0.23	344 52); <i>I</i> ² 01) , df =	= 0% 1 (<i>P</i> = 0).63); I ²	244 = 0%	100.0	0.50 [0.40, 0.60]	-1	–0.5 ATE gr	0 oup Con	0.5 ntrol group	0.1

							(d)						
	ATI	Egrou	р	Cont	rol gro	oup	Weight	Mean difference		Me	ean differe	ence	
Study or Subgroup	Mean SD Total		Mean SD Total		%	IV, Random, 95% C	CI	IV, R	andom, 9	5% CI			
Shih et al, 2001	1.67	0.39	65	1.66	0.36	61	83.5	0.01 [-0.12, 0.14]					
Tang et al, 2020	0.02	1.57	63	0.01	1.68	63	4.4	0.01 [-0.58, 0.58]		-		-	
Yam et al, 2018(0.01%)	15.4	2.07	97	15.3	2.09	93	4.1	0.10 [-0.49, 0.69]					
Yam et al, 2018(0.025%)	15.8	2.06	91	15.3	2.09	93	4.0	0.50 [-0.10, 1.10]					
Yam et al, 2018(0.05%)	15.3	2.1	102	15.3	2.09	93	4.1	0.00 [-0.59, 0.59]		_		-	
Total (95% CI)			419			403	100.0	0.03 [-0.09, 0.15]			•		
Heterogeneity: $chi^2 = 2.52$,	df = 4 (I	P = 0.6	$(4); I^2$	= 0%									
Test for overall effect: $Z = 0$.54 (P =	0.59)							-2	-1	0	1	2
										ATE gr	oup Con	trol group	



	AT	E grou	2	Cont	rol gro	oup	Weight	Mean difference		Mean difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	%	IV, Random, 95% C	Ι	IV, Ra	ndom,	95% CI	
Kumaran et al, 2015	-0.2	0.2	147	-0.17	0.2	168	7.0	-0.03 [-0.07, 0.01]			-		
Shih et al, 2001	0.005	0.013	66	-0.006	0.014	61	33.8	0.01 [0.01, 0.02]					
Yam et al, 2018(0.01%)	0.04	0.06	97	0.05	0.07	93	20.6	-0.01 [-0.03, 0.01]			1		
Yam et al, 2018(0.025%)	0.04	0.08	91	0.05	0.07	93	17.9	-0.01 [-0.03, 0.01]			1		
Yam et al, 2018(0.05%)	0.05	0.08	102	0.05	0.07	93	20.8	0.00 [-0.02, 0.02]					
Total (95% CI)			503			506	100.0	-0.00 [-0.02, 0.01]			•		
Heterogeneity: $tau^2 = 0.00$; $chi^2 = 1$	1.34, d	f = 4	(P = 0.0)	2); I^2 =	= 65%		-	-0.5	-0.25	0	0.25	0.5
Test for overall effect: $Z =$	0.33 (P =	0.74)							0.5	ATE gro	un Co	ntrol group	0.5
										ATE gio	up co	nitioi gioup	
							(f)						
	ATE gi	roup		Contro	l grou	p V	Veight	Mean difference		Mea	n diffe	rence	
Study or Subgroup M	lean S	D To	tal M	lean S	SD T	'otal	%	IV, Random, 95% CI		IV, Ra	ndom,	95% CI	
Kumaran et al, 2015 0	.06 0.	16 14	7 0	0.05 0	0.11	166	47.7	0.03 [-0.00, 0.06]					
Shih et al, 2001 –0	0.01 0.0	012 6	5 0	.033 0.	.014	61	52.3	-0.04 [-0.05, -0.04]					
Total (95% CI)		21	3		2	227	100.0	-0.01 [-0.06, 0.06]			\blacklozenge		
Heterogeneity: $tau^2 = 0.00$; $chi^2 = 2$	21.11. d	f = 1	(P < 0.0)	0001);	$I^2 = 95$	5%					1	
Test for overall effect: $Z =$	0.22 (P =	0.82)			,,				-2	-1	0	1	2
	, i i i i i i i i i i i i i i i i i i i	,								ATE gro	up Co	ontrol group	
							(g)						
	AT	Egroiii)	Cont	rol gra	01110	Weight	Mean difference		Me	an diff	erence	
Study or Subgroup	Mean	SD '	 Total	Mean	SD	Total	%	IV, Random, 95% C	Ι	IV, R	andom	, 95% CI	
Tang et al 2020	-0.06	0.99	63	-0.02	1.07	63	45.8	-0.04 [-0.40, 0.32]				_	
Zhao et al. 2021	-0.25	0.84	40	-0.16	0.66	40	54.2	-0.09[-0.42, 0.24]				_	
21140 07 41, 2021	0.20	0101		0110	0.00	10	0 112	0105 [0112, 012 1]					
Total (95% CI)			103			103	100.0	-0.07 [-0.31, 0.18]			-		
Heterogeneity: $chi^2 = 0.04$	df = 1 (1	P = 0.8	4); <i>I</i> ²	= 0%						1		1	
Test for overall effect: $Z =$	0.54 (P =	0.59)							-2	-1	0	1	2
										ATE gro	oup C	ontrol group	

(h)

FIGURE 4: Changes of adverse effects of near vision (a), BCVA (b), photopic pupil size (c), mesopic pupil size (d), IOP (e), ACD (f), LT (g), and T-BUT (h). BCVA, best-corrected vision acuity; IOP, intraocular pressure; ACD, anterior chamber depth; LT, lens thickness; T-BUT, tear break-up time; and CI, confidence interval.

in subgroup differences in SER ($I^2 = 23.9\%$, p = 0.27; $I^2 = 1.0\%$, p = 0.36), as shown in Figure S3. The results of the sensitivity analysis demonstrated that one study [28], in which the inappropriate randomisation was found, had influenced the data analysis.

5. Discussion

5.1. Main Results. Our meta-analysis confirms that atropine is effective in slowing childhood myopic progression. There was a statistically significant difference among various doses of atropine. Low-dose atropine may be the most prominent dosage. This finding contrasts with a meta-analysis [20] published in 2017 that showed the same efficacy between various doses of atropine, but that analysis included RCTs and cohort studies together to investigate the overall effects of different doses. The previous meta-analysis [17] that included 11 studies and 1815 children and showed a positive effect of atropine, but no stratification by dose or quantification of adverse effects was performed and the 0.01% dose was not included. The next meta-analysis [37] included 7 studies and 1079 children and showed a positive effect of 0.01% atropine, but no significance in refraction values. Our

study identified only high-quality RCTs and quantifies various doses of atropine. We have shown that decreasing the dose of atropine leads to a slowing myopic progression. Conversely, high-dose atropine had no influence on changes in SER, which could be explained by limited number of studies. We conclude that 1% atropine causes a rebound effect with more diopters in the former six months than the latter after discontinuation. The result was different from the study [19] by Chia et al. who identified the effectiveness of 0.01%, 0.1%, and 0.5% atropine in myopic children with no placebo control group, showing that 0.01% atropine rebounded less. This could be explained by quick and continual paralysis function of pupil dilation in the earlier period [38] that needs more RCTs to verify the rebound effects. We analyzed studies with the control group in rebound effects. For adverse effects, accommodation is an important factor in relation to atropine-induced side effects. In the current study, the MD change of -0.71 D in the atropine group was not significantly different from 0.26 D reported by Yam et al. [13] (p = 0.142), but significantly lower than the 4.40 D found by Chia et al. [39] (p = 0.0007). We confirm that high-dose atropine may alleviate AMP, but 0.01% atropine causes no effect on AMP. It may be the reason that high-dose atropine reduces compatible reaction, which may be a possible mechanism to prolong the development of myopia. However, these differences across studies may be related to different methodologies. Comparison of photopic pupil size between studies revealed that the MD increase in the current study was 0.48 mm (95% CI, 0.32 to 0.63) in the 0.01% atropine group, which was not significantly different from the finding of 0.49 mm in the study conducted by Yam et al. [13] (p = 0.6045), but significantly smaller than the 0.91 mm observed by Chia et al. [19] (p = 0.0014). The MD increase in mesopic pupil size was 0.49 mm (95%CI, 0.37 to 0.60) mm in 0.01%~1% atropine groups in the current study, which was significantly higher than the 0.23 (0.46) mm in the study of Yam et al. [13] (p = 0.0001), but significantly lower than the 1.15 (0.78) mm from Chia et al. [19] (p = 0.0017). The small changes in pupil size noted in the present study may explain why subjects rarely complained regarding low-dose atropine use. We recommend using the lowest dose of atropine for therapy, and more clinical trials with doses are needed to investigate rebound effects in long-term application.

5.2. Strength and Limitations. To our best of knowledge, this is the first meta-analysis to systematically evaluate rebound effects of atropine and accommodation dysfunction. We included only high-quality RCTs [13, 15, 16, 23-36] providing evidence-based medical analysis for the use of atropine in controlling myopia. This meta-analysis verified that the effectiveness of atropine in controlling myopia progression was closely related to the dose. A 0.01% atropine might be the optimal dose which could slow the myopia progression and have no influence on accommodation. Meanwhile, the minimal additive effects in BCVA and photopic pupil size dilation were identified in low-dose atropine. Besides, 1.0% atropine had the least rebound effect after discontinuation, especially in the latter six months. The adverse effects of atropine in decreasing accommodation dysfunction were identified in high-dose atropine groups. Although atropine prevents myopia progression effectively, combined with other therapies, such as orthokeratology, and time spent outdoors, Tan et al. reported 0.01% atropine eye drops and orthokeratology can significantly slow the axis elongation compared to the use of orthokeratology alone [30]. Therefore, the effectiveness of the combined application of atropine and orthokeratology needed to be further studied. There were several limitations in our meta-analysis. First, although this meta-analysis had established strict inclusion and exclusion criteria, the heterogeneity was still high after using the subgroup analysis. Because not enough studies examined the rebound effect, different follow-up times of studies were combined in this meta-analysis to investigate the overall effects of different doses, which might be a source of additional heterogeneity. However, through the sensitivity analysis, the results of this meta-analysis were stable and consistent. Secondly, only data in rebound effects of high-dose atropine were available to analyze, but they lack of low-dose atropine measurement. The further determination and rebound effects of various doses required

additional research, and more large-sample, multicenter, and high-quality RCTs will provide strong clinical evidence in the future.

6. Conclusions

In conclusion, the efficacy of atropine is closely associated with dose, and a rebound effect of high-dose atropine is more obvious in the former six months of cessation after discontinuation. The optical dose was reviewed as 0.01% atropine in the treatment of myopia and could be used as a clinically feasible method to control the progression of myopia with fewer accommodation dysfunction and adverse reactions.

Data Availability

All data relevant to the study are included in the article or uploaded as online supplementary information.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this article.

Authors' Contributions

JYY and CWC contributed substantially to the conception and design of this paper, drafted the paper, and carried out statistical analysis. CWC conducted the literature searches and extracted the data from published papers.

Acknowledgments

The authors thank the investigators who contributed to discussions, as well as the writing and review of the manuscript.

Supplementary Materials

FigS1. Method quality of evaluation. Figure S2. Funnel plot of the subgroups. SE, standard deviation. MD, mean difference. SER (A), axial elongation (B), AMP (C), photopic pupil size (D), ACD (E), and total (F). SER, spherical equivalent refraction; AMP, accommodation amplitude; ACD, anterior chamber depth; SE, standard deviation. MD, mean difference; ATE, atropine. Figure S3. Sensitivity Analysis of subgroup differences in SER (A), axial elongation (B), AMP (C), photopic pupil size (D), and ACD (E). SER, spherical equivalent refraction; AMP, accommodation amplitude; ACD, anterior chamber depth; and CI, confidence interval. (*Supplementary Materials*)

References

- D. D. Brown, S. Guo, F. M. Wang, and R. S. Wagner, "Management of high myopia in children," *Journal of Pediatric Ophthalmology & Strabismus*, vol. 55, no. 4, pp. 212–214, 2018.
- [2] E. Dolgin, "The myopia boom," Nature, vol. 519, no. 7543, pp. 276–278, 2015.

- [3] D. I. Flitcroft, M. He, J. B. Jonas et al., "IMI defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies," *Investigative Opthalmology & Visual Science*, vol. 60, no. 3, pp. M20–M30, 2019.
- [4] C. Y. Mak, J. C. Yam, L. J. Chen, S. M. Lee, and A. L. Young, "Epidemiology of myopia and prevention of myopia progression in children in East Asia: a review," *Hong Kong Medical Journal*, vol. 24, pp. 602–609, 2018.
- [5] I. G. Morgan, A. N. French, R. S. Ashby et al., "The epidemics of myopia: aetiology and prevention," *Progress in Retinal and Eye Research*, vol. 62, pp. 134–149, 2018.
- [6] I. G. Morgan, K. Ohno-Matsui, and S.-M. Saw, "Myopia," *The Lancet*, vol. 379, no. 9827, pp. 1739–1748, 2012.
- [7] B. A. Holden, T. R. Fricke, D. A. Wilson et al., "Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050," *Ophthalmology*, vol. 123, no. 5, pp. 1036–1042, 2016.
- [8] J. Chua and T. Y. Wong, "Myopia-the silent epidemic that should not Be ignored," *JAMA ophthalmology*, vol. 134, no. 12, pp. 1363-1364, 2016.
- [9] S. Y. L. Chua, C. Sabanayagam, Y.-B. Cheung et al., "Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children," *Ophthalmic and Physiological Optics*, vol. 36, no. 4, pp. 388–394, 2016.
- [10] J. W. L. Tideman, J. R. Polling, J. R. Vingerling et al., "Axial length growth and the risk of developing myopia in European children," *Acta Ophthalmologica*, vol. 96, no. 3, pp. 301–309, 2018.
- [11] J. Cooper and A. V. Tkatchenko, "A review of current concepts of the etiology and treatment of myopia," *Eye and Contact Lens: Science and Clinical Practice*, vol. 44, no. 4, pp. 231–247, 2018.
- [12] L. Spillmann, "Stopping the rise of myopia in Asia," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 258, no. 5, pp. 943–959, 2020.
- [13] J. C. Yam, Y. Jiang, S. M. Tang et al., "Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control," *Ophthalmology*, vol. 126, pp. 113–124, 2019.
- [14] J. C. Yam, F. F. Li, X. Zhang et al., "Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report," *Ophthalmology*, vol. 127, pp. 910–919, 2020.
- [15] S. Yi, Y. Huang, S. Z. Yu, X. J. Chen, H. Yi, and X. L. Zeng, "Therapeutic effect of atropine 1% in children with low myopia," *Journal of AAPOS: The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus*, vol. 19, pp. 426–429, 2015.
- [16] A. Kumaran, H. M. Htoon, D. Tan, and A. Chia, "Analysis of changes in refraction and biometry of atropine- and placebotreated eyes," *Investigative Opthalmology & Visual Science*, vol. 56, no. 9, pp. 5650–5655, 2015.
- [17] F. F. Li, K. W. Kam, Y. Zhang et al., "Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: lowconcentration atropine for myopia progression study," *Ophthalmology*, vol. 127, pp. 1603–1611, 2020.
- [18] S. L. Pineles, R. T. Kraker, D. K. VanderVeen et al., "Atropine for the prevention of myopia progression in children," *Ophthalmology*, vol. 124, no. 12, pp. 1857–1866, 2017.
- [19] A. Chia, W. H. Chua, L. Wen, A. Fong, Y. Y. Goon, and D. Tan, "Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%,"

American Journal of Ophthalmology, vol. 157, pp. 451–457.e1, 2014.

- [20] Q. Gong, M. Janowski, M. Luo et al., "Efficacy and adverse effects of atropine in childhood myopia," *JAMA ophthalmology*, vol. 135, no. 6, pp. 624–630, 2017.
- [21] Y.-y. Song, H. Wang, B.-S. Wang, H. Qi, Z.-X. Rong, and H.-Z. Chen, "Atropine in ameliorating the progression of myopia in children with mild to moderate myopia: a metaanalysis of controlled clinical trials," *Journal of Ocular Pharmacology and Therapeutics*, vol. 27, no. 4, pp. 361–368, 2011.
- [22] C. Zhao, C. Cai, Q. Ding, and H. Dai, "Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis," *BMC Ophthalmology*, vol. 20, no. 1, p. 478, 2020.
- [23] Q. Zhao and Q. Hao, "Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children," *International Ophthalmology*, vol. 41, no. 3, pp. 1011–1017, 2021.
- [24] W.-H. Chua, V. Balakrishnan, Y.-H. Chan et al., "Atropine for the treatment of childhood myopia," *Ophthalmology*, vol. 113, no. 12, pp. 2285–2291, 2006.
- [25] M. Diaz-Llopis and M. D. Pinazo-Durán, "Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness," *Archivos de la Sociedad Espanola de Oftalmologia*, vol. 93, pp. 182–185, 2018.
- [26] O. Hieda, T. Hiraoka, T. Fujikado et al., "Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study," *Japanese Journal of Ophthalmology*, vol. 65, no. 3, pp. 315–325, 2021.
- [27] R. Saxena, R. Dhiman, V. Gupta, P. Kumar, J. Matalia, and L. Roy, "Atropine for treatment of childhood myopia in India (I-ATOM): multicentric randomized trial," *Ophthalmology*, pp. 79–88, 2021.
- [28] Y.-F. Shih, C.-H. Chen, A.-C. Chou, T.-C. Ho, L. L.-K. Lin, and P.-T. Hung, "Effects of different concentrations of atropine on controlling myopia in myopic children," *Journal of Ocular Pharmacology and Therapeutics*, vol. 15, no. 1, pp. 85–90, 1999.
- [29] Y.-F. Shih, C. K. Hsiao, C.-J. Chen, C.-W. Chang, P. T. Hung, and L. L.-K. Lin, "An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression," *Acta Ophthalmologica Scandinavica*, vol. 79, no. 3, pp. 233– 236, 2001.
- [30] Q. Tan, A. L. Ng, B. N. Choy, G. P. Cheng, V. C. Woo, and P. Cho, "One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial," *Ophthalmic* and Physiological Optics: The Journal of the British College of Ophthalmic Opticians (Optometrists), vol. 40, pp. 557–566, 2020.
- [31] W. T. Tang, M. Tian, S. B. Li, and Q. Yu, "Clinical observation of low-dose Atropine combined with orthokeratology in the treatment of myopia," *International Eye Science*, vol. 20, pp. 1044–1047, 2020.
- [32] L. Tong, X. L. Huang, A. L. T. Koh, X. Zhang, D. T. H. Tan, and W.-H. Chua, "Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine," *Ophthalmology*, vol. 116, no. 3, pp. 572–579, 2009.
- [33] S. J. Vincent, Q. Tan, A. L. K. Ng, G. P. M. Cheng, V. C. P. Woo, and P. Cho, "Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control," *Ophthalmic and Physiological Optics: The Journal of the British College of Ophthalmic Opticians (Optometrists)*, vol. 40, pp. 728–737, 2020.

- [34] Y. R. Wang, H. L. Bian, and Q. Wang, "Atropine 0.5% eyedrops for the treatment of children with low myopia: a randomized controlled trial," *Medicine*, vol. 96, Article ID e7371, 2017.
- [35] M. Y. Yen, J. H. Liu, S. C. Kao, and C. H. Shiao, "Comparison of the effect of atropine and cyclopentolate on myopia," *Annals of Ophthalmology*, vol. 21, pp. 180–187, 1989.
- [36] S. Wei, S.-M. Li, W. An et al., "Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children," *JAMA ophthalmology*, vol. 138, no. 11, pp. 1178–1184, 2020.
- [37] Y. Zhao, K. Feng, R. B. Liu et al., "Atropine 0.01% eye drops slow myopia progression: a systematic review and Metaanalysis," *International Journal of Ophthalmology*, vol. 12, pp. 1337–1343, 2019.
- [38] P. C. Wu and H. K. Kuo, "Accommodation and pupil size in schoolchildren with low concentration of atropine for controlling myopic progression," *Investigative Ophthalmology & Visual Science*, vol. 47, 2006.
- [39] A. Chia, W. H. Chua, Y. B. Cheung et al., "Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2)," *Ophthalmology*, vol. 119, pp. 347–354, 2012.